Do we protect or discriminate? Representation of senior adults in clinical trials

Reports of Practical Oncology and Radiotherapy

Volumn 18, Issue 1, 2013, Pages 6-10

  Kaźmierska, Joanna ^a,b  

^a GREATER POLAND CANCER CENTER   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Cancer; Elderly in clinical trials; Senior adults

Indexed keywords

AGEISM; AGING; ARTICLE; CANCER THERAPY; CLINICAL STUDY; CLINICAL TRIAL (TOPIC); COMORBIDITY; DRUG TOXICITY; EUROPE; EVIDENCE BASED MEDICINE; HUMAN; MEDICAL SPECIALIST; MEDLINE; NEOPLASM; ONCOLOGIST; PATIENT PREFERENCE; PEER REVIEW; PHYSICIAN ATTITUDE; POLYPHARMACY; PRACTICE GUIDELINE; PUBLICATION; QUALITY OF LIFE;

EID: 84875247377     PISSN: 15071367     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rpor.2012.08.006     Document Type: Article

References (29)

1. Center for Evidence Based Medicine University of Oxford. ; 2012. http://www.cebm.net/index.aspx%3Fo=5653.
2. Franceschi S., La Vecchia C. Cancer epidemiology in elderly. Crit Rev Oncol Hematol 2001, 39:219-226.
3. Hutchins L.F., Unger J.M., Crowley J.J., et al. Underrepresentation of patients 65 years of age or older in cancer treatment trials. N Engl J Med 1999, 341:2061-2067.
4. Yee K.W., Pater J.L., Pho L., et al. Enrolment of older patients in cancer treatment trials in Canada: why is age a barrier?. J Clin Oncol 2003, 21:1618-1623.
5. Monfardini S., Sorio R., Boes G.H., et al. Entry and evaluation of elderly patients in European Organisation for Research and Treatment of Cancer (EORTC) new drug development studies. Cancer 1995, 76:333-338.
6. Lewis J.H., Kilgore M.L., Goldman D.P., et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003, 21:1383-1389.
7. Talarico L., Chen G., Pazdur R. Enrolment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol 2004, 22(22):4627-4631.
8. Hosmann I., Karsh M., Klingholz R., et al. Europe's demographic future 2008, The Berlin Institute for Population and Development, Berlin.
9. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). National Comprehensive Cancer Network, Inc.; 2011.
10. Pallis A.G., Fortpied C., Wedding U., et al. EORTC elderly task force position paper: approach to the older cancer patient. Eur J Cancer 2010, 46(9):1502-1513.
11. Aparicio T., Navazesh A., Boutron I., et al. Half of elderly patients routinely treated for colorectal cancer receive a sub-standard treatment. Crit Rev Oncol Hematol 2009, 71(3):249-257.
12. Sargent F.J., Goldberg R.M., Jacobson S.D., et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001, 345(15):1091-1097.
13. Folprecht G., Cunningham D., Ross P., et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: a pooled analysis of clinical trials. Ann Oncol 2004, 15:1330-1338.
14. Muss H.B., Berry D.A., Cirrincione C.T., et al. Adjuvant chemotherapy in older women with early stage breast cancer. N Engl J Med 2009, 360(20):2055-2065.
15. Payne J.K., Hendrix CC Clinical trial recruitment challenges with older adults with cancer. Appl Nurs Res 2010, 23(4):233-237.
16. Kemeny M.M., Peterson B.L., Kornblith A.B., et al. Bariers to clinical trial participation by older women with breast cancer. J Clin Oncol 2003, 12(15):2268-2275.
17. Food and Drug Administration November 1989 - Guideline to the study of drugs likely to be used in elderly. Fed Regist 1994, 59(102):39398-39400.
18. Aapro M.S., Kohne C.H., Cohen H.J., et al. Never too old? Age should not be a barrier to enrolment in cancer clinical trials. Oncologist 2005, 10(3):198-204.
19. Townsley C.A., Selby R., Siu L.L. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol 2005, 23:3112-3124.
20. Extermann M., Aapro M., Bernabei R., et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 2005, 55(3):241-252.
21. Cardia J., Calcada C., Pereira H. Treatment of lung cancer in elderly: influence on comorbidity on toxicity and survival. Rep Pract Oncol Radiother 2011, 16(2):45-48.
22. Gridelli C., Maione P., Barletta E. Individualised chemotherapy for elderly patients with nonsmall cell lung cancer. Curr Opin Oncol 2002, 14(2):199-203.
23. Popa M., Wallace K., Brunello A., et al. The impact of polypharmacy on toxicity from chemotherapy in elderly patients: focus on cytochrome P-450 inhibition and protein binding effects. Proc Am Soc Clin Oncol 2008, 26:503s.
24. Basche M., Baron A.E., Eckhardt S.G., et al. Barriers to enrolment of elderly adults in early-phase cancer clinical trials. J Oncol Pract 2008, 4(4):162-168.
25. Kornbilth A.B., Kemeny M., Peterson B.L., et al. Survey of oncologists' perceptions of barriers to accrual of older patients with breast carcinoma to clinical trials. Cancer 2002, 95:989-996.
26. He X., Clarke S.J., McLachlan A.J. Clinical paharmacology of chemotherapy agents in older people with cancer. Curr Gerontol Geriat Res 2011, 6:1-6.
27. Townsley C.A., Pond G.R., Oza A.M., et al. Evaluation of adverse events experienced by older patients participating in studies of molecularly targeted agents alone or in combination. Clin Cancer Res 2006, 12:2141-2149.
28. Cherubini A., Oristrell J., Pla X., et al. The persistent exclusion of older patients from ongoing clinical trials regarding heart failure. Arch Intern Med 2011, 171(6):550-556.
29. Pallis A.G., Gridelli C., van Meerbeeck J.P., et al. EORTC elderly task force and lung cancer group and International Society for Geriatric Oncology (SIOG) experts' opinion for the treatment of non-small-cell lung cancer in elderly population. Ann Oncol 2010, 21:692-706.